Valiant Laboratories IPO
Valiant Laboratories IPO — date, price band, lot size & details 2023
Valiant Laboratories listed on 6 Oct 2023 at ₹162.15, 15.8% above the ₹140 issue price.
Valiant Laboratories makes paracetamol as an active pharmaceutical ingredient from a single plant at Palghar, Maharashtra. Its total income was Rs 338.77 crore in FY2023.
Stock price
Valiant Laboratories is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 November.
- Open 27 Sep 2023
- Close 03 Oct 2023
- Allotment 05 Oct 2023
- Refund/credit 06 Oct 2023
- Listing 06 Oct 2023
Issue summary
The terms of the offer, as filed.
| IPO Dates | 27 Sep to 3 Oct, 2023 |
|---|---|
| Price Band | ₹133 – ₹140 |
| Face Value | ₹10 |
| Lot Size | 105 Shares |
| Issue Size | ₹152.46 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,700 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 105 shares at the ₹140 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 105 | ₹14,700 |
| Retail (max) | 13 | 1,365 | ₹1,91,100 |
| S-HNI (min) | 14 | 1,470 | ₹2,05,800 |
| S-HNI (max) | 68 | 7,140 | ₹9,99,600 |
| B-HNI (min) | 69 | 7,245 | ₹10,14,300 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Total income rose from Rs 183.78 crore in FY2021 to Rs 338.77 crore in FY2023.
- 02The pre-issue P/E was 15.71 at the upper band of Rs 140, based on EPS of Rs 8.91.
- 03The whole Rs 152.46 crore issue was fresh capital for a new facility through its subsidiary.
- 04Net worth was Rs 100.49 crore on 31 March 2023, against borrowing of Rs 59.40 crore.
- 05The source puts return on net worth at 28.86%.
Risks · 5
- 01Profit after tax fell from Rs 30.59 crore in FY2021 to Rs 29.00 crore in FY2023, despite higher sales.
- 02It depends on one product, paracetamol, and on 1 manufacturing facility.
- 03Its main raw material is imported from China and Cambodia, so supply and price shocks matter. The source puts the PAT margin at 8.56%.
- 04Total borrowing rose from Rs 0.35 crore on 31 March 2021 to Rs 59.40 crore on 31 March 2023.
- 05Promoters and the promoter group held 100% before the issue and 74.94% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Valiant Laboratories offer document.
| Metric | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 212.76 | 181.81 | 106.31 |
| Total Income | 338.77 | 293.47 | 183.78 |
| Profit After Tax | 29.00 | 27.50 | 30.59 |
| NET Worth | 100.49 | 71.46 | 88.58 |
| Total Borrowing | 59.40 | 60.68 | 0.35 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Valiant Laboratories RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Valiant Laboratories IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹8.91 | ₹6.67 |
| P/E Ratio (x) | 15.71 | 20.99 |
| Market Cap at Offer Price (₹ Cr) | ₹455.67 | ₹608.70 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹140 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹134.32 Cr of the issue is earmarked to named objects.
About the company
It operates out of a single manufacturing facility at Boisar, Palghar, Maharashtra, which also has an R&D facility with an analytical laboratory.
It imports para amino phenol, the key raw material for paracetamol, from China and Cambodia.
The IPO was Rs 152.46 crore and was entirely fresh issue. Rs 80.00 crore was planned for its subsidiary VASPL to set up a new facility and Rs 45.00 crore for VASPL's working capital.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Valiant Laboratories IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Unistone Capital
17 issues handled (15 mainboard, 2 SME)Best listing: Sigachi Industries (+249.7%). Weakest: Fabtech Technologies (0.0%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Valiant Laboratories?
The current Grey Market Premium is ₹25, or 18% over the issue price.
What is the Valiant Laboratories IPO price band?
₹133 to ₹140, on a face value of ₹10.
When is the allotment?
The basis of allotment is 5 October 2023, with listing on 6 October 2023.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
